Nothing Special   »   [go: up one dir, main page]

SG11201811491YA - Quinazoline and indole compounds to treat medical disorders - Google Patents

Quinazoline and indole compounds to treat medical disorders

Info

Publication number
SG11201811491YA
SG11201811491YA SG11201811491YA SG11201811491YA SG11201811491YA SG 11201811491Y A SG11201811491Y A SG 11201811491YA SG 11201811491Y A SG11201811491Y A SG 11201811491YA SG 11201811491Y A SG11201811491Y A SG 11201811491YA SG 11201811491Y A SG11201811491Y A SG 11201811491YA
Authority
SG
Singapore
Prior art keywords
international
rule
pct
applicant
new haven
Prior art date
Application number
SG11201811491YA
Inventor
Jason Allan Wiles
Avinash Phadke
Original Assignee
Achillion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Achillion Pharmaceuticals Inc filed Critical Achillion Pharmaceuticals Inc
Publication of SG11201811491YA publication Critical patent/SG11201811491YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3834—Aromatic acids (P-C aromatic linkage)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property MD 1101111 0 DOI HIM 011101 0 01111111HH11111111111111111111111111 Organization 0 International Bureau (10) International Publication Number (43) International Publication Date .....0\"\"\" WO 2018/005552 Al 04 January 2018 (04.01.2018) W I PO I PCT (51) International Patent Classification: A61K 31/517 (2006.01) C07D 401/14 (2006.01) Published: A61K 31/395 (2006.01) — with international search report (Art 21(3)) — before the expiration of the time limit for amending the (21) International Application Number: claims and to be republished in the event of receipt of PCT/US2017/039587 amendments (Rule 48.2(h)) (22) International Filing Date: 27 June 2017 (27.06.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/355,273 27 June 2016 (27.06.2016) US 62/471,799 15 March 2017 (15.03.2017) US (71) Applicant: ACHILLION PHARMACEUTICALS, INC. [US/US]; 300 George Street, New Haven, CT 06511 (US). (72) Inventors: WILES, Jason Allan; c/o Achillion Pharma- ceuticals, Inc., 300 George Street, New Haven, CT 06511 _ (US). PHADKE, Avinash; c/o Achillion Pharmaceuticals, Inc., 300 George Street, New Haven, CT 06511 (US). — = Agent: BELLOWS, Brent R. et al.; Knowles Intellectu- (74) al Property Strategies, LLC, 400 Perimeter Center Terrace, Suite 200, Atlanta, GA 30346 (US). = Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. = (81) = — = = = = = = = Designated States (unless otherwise indicated, for every (84) = kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). = = = — = — 1-1 ..! Declarations under Rule 4.17: ei — as to applicant's entitlement to apply for and be granted a kir) patent (Rule 4.170) ir) — as to the applicant's entitlement to claim the priority of the kir) 0 earlier application (Rule 4.17(iii)) 0 --.... 00 1-1 (54) Title: QUINAZOLINE AND INDOLE COMPOUNDS TO TREAT MEDICAL DISORDERS 0 ei (57) : Compounds, methods of use, and processes for making inhibitors of Complement Factor B are provided.
SG11201811491YA 2016-06-27 2017-06-27 Quinazoline and indole compounds to treat medical disorders SG11201811491YA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662355273P 2016-06-27 2016-06-27
US201762471799P 2017-03-15 2017-03-15
PCT/US2017/039587 WO2018005552A1 (en) 2016-06-27 2017-06-27 Quinazoline and indole compounds to treat medical disorders

Publications (1)

Publication Number Publication Date
SG11201811491YA true SG11201811491YA (en) 2019-01-30

Family

ID=60787571

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201811491YA SG11201811491YA (en) 2016-06-27 2017-06-27 Quinazoline and indole compounds to treat medical disorders

Country Status (13)

Country Link
US (3) US10961252B2 (en)
EP (2) EP3448389B1 (en)
JP (2) JP7057290B2 (en)
KR (1) KR20190036520A (en)
CN (1) CN109414441A (en)
AU (1) AU2017290593A1 (en)
CA (1) CA3029262A1 (en)
ES (1) ES2902006T3 (en)
IL (1) IL263783A (en)
MX (1) MX2018016046A (en)
RU (1) RU2018145364A (en)
SG (1) SG11201811491YA (en)
WO (1) WO2018005552A1 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106397592A (en) * 2015-07-31 2017-02-15 苏州康宁杰瑞生物科技有限公司 Single-domain antibody directed at programmed death ligand (PD-L1) and derived protein thereof
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
EP3340983B1 (en) 2015-08-26 2023-10-04 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
SG11201811491YA (en) * 2016-06-27 2019-01-30 Achillion Pharmaceuticals Inc Quinazoline and indole compounds to treat medical disorders
CA3053818A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
WO2018160892A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for treatment of medical disorders
US20190038623A1 (en) 2017-08-02 2019-02-07 Achillion Pharmaceuticals, Inc. Therapeutic regimens for treatment of paroxysmal nocturnal hemoglobinuria
WO2020051532A2 (en) 2018-09-06 2020-03-12 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for the treatment of medical disorders
WO2020051538A1 (en) 2018-09-06 2020-03-12 Achillion Pharmaceuticals, Inc. Morphic forms of complement factor d inhibitors
CA3114039A1 (en) 2018-09-25 2020-04-02 Achillion Pharmaceuticals, Inc. Morphic forms of complement factor d inhibitors
GB201905810D0 (en) * 2019-04-25 2019-06-05 Volution Immuno Pharmaceuticals Sa Method of treatment
JOP20220113A1 (en) * 2019-11-26 2023-01-30 Omeros Corp Methods for treating and/or preventing idiopathic pneumonia syndrome (ips) and/or capillary leak syndrome (cls) and/or engraftment syndrome (es) and/or fluid overload (fo) associated with hematopoietic stem cell transplant
EP4107166A4 (en) * 2020-02-20 2024-06-26 Achillion Pharmaceuticals, Inc. Heteroaryl compounds for treatment of complement factor d mediated disorders
US20210335448A1 (en) * 2020-04-27 2021-10-28 Advaita Corporation Methods of identifying treatments using differentially expressed genes
EP4194449A4 (en) * 2020-08-07 2024-03-20 Shanghai Meiyue Biotech Development Co., Ltd. Heterocyclic compound, preparation method therefor and use thereof
IL308491A (en) 2020-08-07 2024-01-01 Shanghai Meiyue Biotech Dev Co Ltd Complement factor b inhibitor, and pharmaceutical composition thereof, preparation method therefor and use thereof
WO2022143940A1 (en) * 2020-12-30 2022-07-07 南京明德新药研发有限公司 Series of piperidine-substituted benzoic acid compounds, and use thereof
CN112940825B (en) * 2021-02-06 2022-05-13 中国科学院兰州化学物理研究所 Application of silicon phosphide quantum dots as lubricating oil additive, lubricating oil and preparation method and application thereof
AU2022259328A1 (en) * 2021-04-16 2023-11-09 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Bicyclic substituted aromatic carboxylic acid compounds
EP4346812A2 (en) * 2021-06-03 2024-04-10 Chinook Therapeutics, Inc. Substituted indole compounds and methods of use thereof
WO2023020566A1 (en) * 2021-08-18 2023-02-23 四川海思科制药有限公司 Benzo nitrogen-containing heteroaromatic ring derivative and use thereof in medicine
KR20240090506A (en) * 2021-10-27 2024-06-21 한서 바이오 엘엘씨 Piperidinyl indole derivatives, methods for their preparation and medicinal uses
WO2023143293A1 (en) * 2022-01-26 2023-08-03 上海美悦生物科技发展有限公司 Salt type and crystal form of complement factor b inhibitor, and preparation method therefor and application thereof
CN114921071B (en) * 2022-03-13 2023-07-14 宁波大学 Antibacterial nanocellulose/PHBV composite material and preparation method thereof
WO2023237041A1 (en) * 2022-06-10 2023-12-14 正大天晴药业集团股份有限公司 Bicyclic substituted aromatic carboxylic acid ester compound
WO2023246677A1 (en) * 2022-06-20 2023-12-28 深圳信立泰药业股份有限公司 Indole-phenylpiperidine compound, method for preparing same, and use thereof
TW202415654A (en) * 2022-06-30 2024-04-16 大陸商江蘇恒瑞醫藥股份有限公司 Pharmaceutically acceptable salt and crystalline form of nitrogen-bridged heterocyclic derivative and preparation method thereof
WO2024017299A1 (en) * 2022-07-20 2024-01-25 正大天晴药业集团股份有限公司 Crystal of bridged heterocycle substituted benzoic acid derivative or salt thereof, and preparation method therefor
TW202426432A (en) * 2022-09-10 2024-07-01 大陸商江蘇豪森藥業集團有限公司 2-substituted piperidine derivatives, preparation methods and medicinal uses thereof
WO2024099458A1 (en) * 2022-11-11 2024-05-16 上海医药工业研究院有限公司 Piperidine-substituted benzoic acid compound, and pharmaceutical composition and use thereof
WO2024175028A1 (en) * 2023-02-22 2024-08-29 西藏海思科制药有限公司 Pharmaceutical composition of benzo nitrogen heteroaromatic ring derivative and use thereof in medicine
CN118684668A (en) * 2023-03-21 2024-09-24 上海美悦生物科技发展有限公司 Spiro compound, pharmaceutical composition, preparation method and application thereof

Family Cites Families (214)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB929406A (en) 1958-12-22 1963-06-19 Upjohn Co A process for the production of encapsulated material
GB929401A (en) 1958-12-22 1963-06-19 Upjohn Co Encapsulated emulsions and processes for their preparation
GB969808A (en) 1962-06-08 1964-09-16 Boots Pure Drug Co Ltd Anthelmintic compositions and compounds
IT1148784B (en) 1980-04-09 1986-12-03 Eurand Spa PROCEDURE FOR THE PREPARATION OF MICRO CAPSULES IN A LIQUID VEHICLE
US4946929A (en) 1983-03-22 1990-08-07 Massachusetts Institute Of Technology Bioerodible articles useful as implants and prostheses having predictable degradation rates
US4794000A (en) 1987-01-08 1988-12-27 Synthetic Blood Corporation Coacervate-based oral delivery system for medically useful compositions
US4638045A (en) 1985-02-19 1987-01-20 Massachusetts Institute Of Technology Non-peptide polyamino acid bioerodible polymers
US4806621A (en) 1986-01-21 1989-02-21 Massachusetts Institute Of Technology Biocompatible, bioerodible, hydrophobic, implantable polyimino carbonate article
US5804178A (en) 1986-11-20 1998-09-08 Massachusetts Institute Of Technology Implantation of cell-matrix structure adjacent mesentery, omentum or peritoneum tissue
US5736372A (en) 1986-11-20 1998-04-07 Massachusetts Institute Of Technology Biodegradable synthetic polymeric fibrous matrix containing chondrocyte for in vivo production of a cartilaginous structure
CA1340581C (en) 1986-11-20 1999-06-08 Joseph P. Vacanti Chimeric neomorphogenesis of organs by controlled cellular implantation using artificial matrices
US5019379A (en) 1987-07-31 1991-05-28 Massachusetts Institute Of Technology Unsaturated polyanhydrides
US5110927A (en) 1987-12-31 1992-05-05 The United States Of America As Represented By The Department Of Health And Human Services Prazosin analog with increased selectivity and duration of action
JP2528706B2 (en) 1988-05-30 1996-08-28 ゼリア新薬工業株式会社 Pharmaceutical composition of dihydropyridine compound
GB8819110D0 (en) 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
US5010167A (en) 1989-03-31 1991-04-23 Massachusetts Institute Of Technology Poly(amide-and imide-co-anhydride) for biological application
US5019400A (en) 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
US5013557A (en) 1989-10-03 1991-05-07 Warner-Lambert Company Taste masking compositions comprising spray dried microcapsules containing sucralfate and methods for preparing same
KR0182801B1 (en) 1991-04-16 1999-05-01 아만 히데아키 Method of manufacturing solid dispersion
TW209174B (en) 1991-04-19 1993-07-11 Takeda Pharm Industry Co Ltd
GB9206757D0 (en) 1992-03-27 1992-05-13 Ferring Bv Novel peptide receptor ligands
AU4198793A (en) 1992-07-24 1994-01-27 Takeda Chemical Industries Ltd. Microparticle preparation and production thereof
US5399665A (en) 1992-11-05 1995-03-21 Massachusetts Institute Of Technology Biodegradable polymers for cell transplantation
US5512600A (en) 1993-01-15 1996-04-30 Massachusetts Institute Of Technology Preparation of bonded fiber structures for cell implantation
US5514378A (en) 1993-02-01 1996-05-07 Massachusetts Institute Of Technology Biocompatible polymer membranes and methods of preparation of three dimensional membrane structures
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5565215A (en) 1993-07-23 1996-10-15 Massachusettes Institute Of Technology Biodegradable injectable particles for imaging
GB9322014D0 (en) 1993-10-26 1993-12-15 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
SE9401108D0 (en) 1994-03-31 1994-03-31 Leiras Oy Ophthalmic composition I
SE9401109D0 (en) 1994-03-31 1994-03-31 Leiras Oy Opthalmic composition II
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
GB9412273D0 (en) 1994-06-18 1994-08-10 Univ Nottingham Administration means
IT1271679B (en) 1994-07-18 1997-06-04 Mediolanum Farmaceutici Srl PHENYL CARBAMATE DERIVATIVES FOR USE AS AN ANTICOLINESTERASIC
US6007845A (en) 1994-07-22 1999-12-28 Massachusetts Institute Of Technology Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
US5716404A (en) 1994-12-16 1998-02-10 Massachusetts Institute Of Technology Breast tissue engineering
JP3893439B2 (en) 1994-12-19 2007-03-14 第一製薬株式会社 Sustained release granular preparation and method for producing the same
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
US6413539B1 (en) 1996-10-31 2002-07-02 Poly-Med, Inc. Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof
US6123727A (en) 1995-05-01 2000-09-26 Massachusetts Institute Of Technology Tissue engineered tendons and ligaments
GB9515182D0 (en) 1995-07-24 1995-09-20 Co Ordinated Drug Dev Improvements in and relating to powders for use in dry powder inhalers
JP3938938B2 (en) 1995-07-26 2007-06-27 協和醗酵工業株式会社 Solid dispersion or solid dispersion formulation of xanthine derivative
WO1997011698A1 (en) 1995-09-29 1997-04-03 Merck & Co., Inc. ALPHA 1b ADRENERGIC RECEPTOR ANTAGONISTS
US5747490A (en) 1995-09-29 1998-05-05 Merck & Co., Inc. Alpha 1b adrenergic receptor antagonists
US6095148A (en) 1995-11-03 2000-08-01 Children's Medical Center Corporation Neuronal stimulation using electrically conducting polymers
WO1997020820A1 (en) 1995-12-01 1997-06-12 Novartis Ag Heteroaryl compounds
NZ325248A (en) 1995-12-23 1999-09-29 Pfizer Res & Dev Quinoline and quinazoline compounds useful in therapy
US5902599A (en) 1996-02-20 1999-05-11 Massachusetts Institute Of Technology Biodegradable polymer networks for use in orthopedic and dental applications
ES2198579T3 (en) 1996-07-01 2004-02-01 Universiteit Utrecht HYDROGELS HYDROLIZABLE FOR CONTROLLED RELEASE.
US6395302B1 (en) 1996-11-19 2002-05-28 Octoplus B.V. Method for the preparation of microspheres which contain colloidal systems
EP0842657A1 (en) 1996-11-19 1998-05-20 OctoPlus B.V. Microspheres for controlled release and processes to prepare these microspheres
AU7808198A (en) 1997-06-03 1998-12-21 Biocryst Pharmaceuticals, Inc. Novel compounds useful in the complement, coagulat and kallikrein pathways and method for their preparation
JPH1123485A (en) 1997-07-07 1999-01-29 Tani Denki Kogyo Kk Method and apparatus for inspecting substrate
US5837752A (en) 1997-07-17 1998-11-17 Massachusetts Institute Of Technology Semi-interpenetrating polymer networks
DK0901786T3 (en) 1997-08-11 2007-10-08 Pfizer Prod Inc Solid pharmaceutical dispersions with increased bioavailability
US6632922B1 (en) 1998-03-19 2003-10-14 The Regents Of The University Of California Methods and compositions for controlled polypeptide synthesis
US6686446B2 (en) 1998-03-19 2004-02-03 The Regents Of The University Of California Methods and compositions for controlled polypeptide synthesis
US6506577B1 (en) 1998-03-19 2003-01-14 The Regents Of The University Of California Synthesis and crosslinking of catechol containing copolypeptides
US6410561B1 (en) 1998-03-26 2002-06-25 Japan Tobacco Inc. Amide derivatives and nociceptin antagonists
AU1705100A (en) 1998-10-09 2000-05-01 Musc Foundation For Research Development Blocking factor b to treat complement-mediated immune disease
GB9827145D0 (en) 1998-12-09 1999-02-03 Co Ordinated Drug Dev Improvements in or relating to powders
JP2000281660A (en) 1999-03-29 2000-10-10 Sumitomo Pharmaceut Co Ltd Quinazoline derivative
US6287588B1 (en) 1999-04-29 2001-09-11 Macromed, Inc. Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof
IT1312310B1 (en) 1999-05-07 2002-04-15 Recordati Ind Chimica E Farma USE OF SELECTIVE 1B ADRENERGIC RECEPTOR ANTAGONISTS TO IMPROVE SEXUAL DYSFUNCTION
GB9927011D0 (en) 1999-11-16 2000-01-12 Advanced Phytonics Ltd Method for the production of particles
CA2395129C (en) 1999-12-20 2008-12-16 Nicholas J. Kerkhof Process for producing nanometer particles by fluid bed spray-drying
EE200200357A (en) 1999-12-23 2003-10-15 Pfizer Products Inc. Pharmaceutical compositions providing increased concentrations of the drug substance
CA2395333C (en) 1999-12-23 2009-01-13 Pfizer Products Inc. Hydrogel-driven drug dosage form
MXPA02008361A (en) 2000-02-28 2004-05-17 Genesegues Inc Nanocapsule encapsulation system and method.
WO2001068615A1 (en) 2000-03-13 2001-09-20 Chemrx Advanced Technologies, Inc. Quinazoline synthesis
CA2404737C (en) 2000-04-03 2010-06-29 Santen Pharmaceutical Co., Ltd. Drug delivering substance containing polyalkylene glycol and phospholipid covalently bonded to drug
GB0009469D0 (en) 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formalities for use in inhaler devices
GB0009468D0 (en) 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formulations for use in inhaler devices
US6589549B2 (en) 2000-04-27 2003-07-08 Macromed, Incorporated Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
DK1913939T3 (en) 2000-06-27 2017-09-18 Vectura Ltd Formulations for use in inhalers
GB2364919A (en) 2000-07-21 2002-02-13 Cambridge Consultants Inhalers
GB0021024D0 (en) 2000-08-29 2000-10-11 Glaxo Group Ltd Inhalation device
ATE537845T1 (en) 2000-10-31 2012-01-15 Pr Pharmaceuticals Inc METHOD FOR PRODUCING FORMULATIONS FOR IMPROVED DELIVERY OF BIOACTIVE MOLECULES
DE60140268D1 (en) 2000-11-30 2009-12-03 Vectura Ltd PARTICLES FOR USE IN A PHARMACEUTICAL COMPOSITION
WO2003020797A1 (en) 2001-08-30 2003-03-13 The Regents Of The University Of California Transition metal initiators for controlled poly (beta-peptide) synthesis from beta-lactam monomers
GB0122318D0 (en) 2001-09-14 2001-11-07 Novartis Ag Organic compounds
CA2474835A1 (en) 2002-02-01 2003-08-07 Pfizer Products Inc. Immediate release dosage forms containing solid drug dispersions
EP1567487A4 (en) 2002-11-15 2005-11-16 Bristol Myers Squibb Co Open chain prolyl urea-related modulators of androgen receptor function
US20050009910A1 (en) 2003-07-10 2005-01-13 Allergan, Inc. Delivery of an active drug to the posterior part of the eye via subconjunctival or periocular delivery of a prodrug
JP2007505831A (en) 2003-09-15 2007-03-15 ベクトゥラ・リミテッド Pharmaceutical composition for treating premature ejaculation by pulmonary inhalation
WO2005027906A1 (en) 2003-09-18 2005-03-31 Macusight, Inc. Transscleral delivery
ES2383689T3 (en) 2003-09-23 2012-06-25 University Of North Carolina At Chapel Hill Photocurable perfluoropolyethers for use as novel materials in microfluidic devices
SE0302665D0 (en) 2003-10-07 2003-10-07 Astrazeneca Ab Novel Process
WO2005044186A2 (en) 2003-10-28 2005-05-19 Glaxo Group Limited Inhalable pharmaceutical formulations employing desiccating agents and methods of administering the same
WO2005101466A2 (en) 2003-12-19 2005-10-27 The University Of North Carolina At Chapel Hill Methods for fabricating isolated micro- and nano- structures using soft or imprint lithography
WO2005072710A2 (en) 2004-01-28 2005-08-11 Johns Hopkins University Drugs and gene carrier particles that rapidly move through mucous barriers
GB0407627D0 (en) 2004-04-02 2004-05-05 Vectura Ltd Corkscrew pump
CA2563895C (en) 2004-04-13 2012-10-16 Synta Pharmaceuticals Corp. Disalt inhibitors of il-12 production
ES2246694B1 (en) 2004-04-29 2007-05-01 Instituto Cientifico Y Tecnologico De Navarra, S.A. PEGILATED NANOPARTICLES.
US8512738B2 (en) 2004-04-30 2013-08-20 Allergan, Inc. Biodegradable intravitreal tyrosine kinase implants
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US7771742B2 (en) 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
JP2007269629A (en) 2004-06-21 2007-10-18 Astellas Pharma Inc Quinazoline derivative
PL370285A1 (en) 2004-09-23 2006-04-03 Glaxosmithkline Pharmaceuticals Spółka Akcyjna Powder inhaler
PT1855652E (en) 2005-01-28 2016-01-26 Bend Res Inc Drying of drug-containing particles
EP1844078B1 (en) 2005-02-03 2016-09-28 Bend Research, Inc Pharmaceutical compositions with enhanced performance
US8663639B2 (en) 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
PL1848431T3 (en) 2005-02-09 2016-08-31 Santen Pharmaceutical Co Ltd Liquid formulations for treatment of diseases or conditions
AU2006282042B2 (en) 2005-06-17 2011-12-22 The University Of North Carolina At Chapel Hill Nanoparticle fabrication methods, systems, and materials
EP1922364A4 (en) 2005-08-09 2010-04-21 Univ North Carolina Methods and materials for fabricating microfluidic devices
US20070071756A1 (en) 2005-09-26 2007-03-29 Peyman Gholam A Delivery of an agent to ameliorate inflammation
WO2007056561A2 (en) 2005-11-09 2007-05-18 Liquidia Technologies, Inc. Medical device, materials, and methods
AU2006329202A1 (en) 2005-12-21 2007-06-28 Painceptor Pharma Corporation Compositions and methods for modulating gated ion channels
WO2007076358A1 (en) 2005-12-23 2007-07-05 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
US8944804B2 (en) 2006-01-04 2015-02-03 Liquidia Technologies, Inc. Nanostructured surfaces for biomedical/biomaterial applications and processes thereof
EP1986603A2 (en) 2006-01-13 2008-11-05 SurModics, Inc. Microparticle containing matrices for drug delivery
CN103127100A (en) 2006-03-23 2013-06-05 参天制药株式会社 Formulation and method for vascular permeability-related diseases or conditions
US20080166411A1 (en) 2006-04-10 2008-07-10 Pfizer Inc Injectable Depot Formulations And Methods For Providing Sustained Release Of Poorly Soluble Drugs Comprising Nanoparticles
WO2007133808A2 (en) 2006-05-15 2007-11-22 Liquidia Technologies, Inc. Nano-particles for cosmetic applications
US20100016293A1 (en) 2006-07-03 2010-01-21 Rogier Adriaan Smits Quinazolines and Related Heterocyclic Compounds, and Their Therapeutic Use
WO2008013952A2 (en) 2006-07-27 2008-01-31 The University Of North Carolina At Chapel Hill Nanoparticle fabrication methods, systems, and materials for fabricating artificial red blood cells
GB0617480D0 (en) 2006-09-06 2006-10-18 Univ Sheffield Novel nanoparticles
ATE498393T1 (en) 2006-09-08 2011-03-15 Univ Johns Hopkins COMPOSITIONS FOR INTENSIVATING TRANSPORT THROUGH THE MUCOSA
US9022970B2 (en) 2006-10-16 2015-05-05 Alcon Research, Ltd. Ophthalmic injection device including dosage control device
PL2091514T3 (en) 2006-11-09 2014-03-31 Alcon Res Ltd Water insoluble polymer matrix for drug delivery
WO2008100304A2 (en) 2006-11-15 2008-08-21 The University Of North Carolina At Chapel Hill Polymer particle composite having high fidelity order, size, and shape particles
NZ578873A (en) 2007-03-01 2012-01-12 Wellstat Ophthalmics Corp Complement factor B analogs and uses for the treatment of complement mediated disease such as inflammation
WO2009051837A2 (en) 2007-10-12 2009-04-23 Massachusetts Institute Of Technology Vaccine nanotechnology
US20090203709A1 (en) 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical Dosage Form For Oral Administration Of Tyrosine Kinase Inhibitor
JP5586579B2 (en) 2008-04-04 2014-09-10 ネクシスビジョン， インコーポレイテッド Treatment device for pain management and vision
US8945527B2 (en) 2008-04-25 2015-02-03 The University Of North Carolina At Chapel Hill Degradable compounds and methods of use thereof, particularly with particle replication in non-wetting templates
WO2009132206A1 (en) 2008-04-25 2009-10-29 Liquidia Technologies, Inc. Compositions and methods for intracellular delivery and release of cargo
EP2133334A1 (en) 2008-06-09 2009-12-16 DAC S.r.l. Heterocyclic derivatives as HDAC inhibitors
WO2010009087A1 (en) 2008-07-15 2010-01-21 Eyegate Pharmaceuticals, Inc. Iontophoretic delivery of a controlled-release formulation in the eye
MX2011003759A (en) 2008-10-08 2011-05-03 Astrazeneca Ab Inhalation device and method of dispensing medicament.
BRPI0923282B1 (en) 2008-12-05 2019-09-03 Liquidia Tech Inc method for producing standardized materials
US8952052B2 (en) 2008-12-30 2015-02-10 Hill's Pet Nutrition, Inc. Use of lipoic acid for treating or preventing degenerative joint conditions, osteoarthritis, cartilage damage, and related disorders in companion animals
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
US8399006B2 (en) 2009-01-29 2013-03-19 Forsight Vision4, Inc. Posterior segment drug delivery
WO2010091187A2 (en) 2009-02-04 2010-08-12 The Brigham And Women's Hospital, Inc. Polymeric nanoparticles with enhanced drug-loading and methods of use thereof
JP5643233B2 (en) * 2009-02-10 2014-12-17 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプＪａｎｓｓｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａ Ｎａａｍｌｏｚｅ Ｖｅｎｎｏｏｔｓｃｈａｐ Quinazolinone as a prolyl hydroxylase inhibitor
JP5969212B2 (en) 2009-02-10 2016-08-17 シヴィダ・ユーエス・インコーポレイテッドPsivida Us, Inc. Ophthalmic trocar assembly
CN102421479A (en) 2009-02-26 2012-04-18 北卡罗来纳大学查珀尔希尔分校 Interventional drug delivery system and associated methods
US10952965B2 (en) 2009-05-15 2021-03-23 Baxter International Inc. Compositions and methods for drug delivery
JP5695035B2 (en) 2009-06-03 2015-04-01 フォーサイト・ビジョン５・インコーポレイテッドＦｏｒｓｉｇｈｔ Ｖｉｓｉｏｎ５，Ｉｎｃ． Anterior eye drug supply
US20120114554A1 (en) 2009-07-13 2012-05-10 Liquidia Technologies, Inc. Engineered Aerosol Particles, And Associated Methods
TWI492769B (en) 2009-09-23 2015-07-21 Alcon Res Ltd Injectable aqueous ophthalmic composition and method of use therefor
WO2011050327A1 (en) 2009-10-23 2011-04-28 Forsight Labs Llc Corneal denervation for treatment of ocular pain
WO2011050365A1 (en) 2009-10-23 2011-04-28 Forsight Labs, Llc Conformable therapeutic shield for vision and pain
TWI478730B (en) 2009-12-03 2015-04-01 Alcon Res Ltd Ophthalmic emulsion
EP2538929A4 (en) 2010-02-25 2014-07-09 Univ Johns Hopkins Sustained delivery of therapeutic agents to an eye compartment
US20130071349A1 (en) 2010-03-02 2013-03-21 Allergan, Inc. Biodegradable polymers for lowering intraocular pressure
MX2012012826A (en) 2010-05-05 2013-01-28 Alcon Res Ltd Stabilized ophthalmic galactomannan formulations.
WO2011153349A1 (en) 2010-06-02 2011-12-08 Alcon Research, Ltd. Ophthalmic compositions comprising pbo-peo-pbo block copolymers
DK2600812T3 (en) 2010-08-05 2021-10-18 Forsight Vision4 Inc Apparatus for treating an eye
DK2600930T3 (en) 2010-08-05 2021-03-01 Forsight Vision4 Inc Injection device for drug delivery
CA2807537C (en) 2010-08-05 2018-09-18 Forsight Vision4, Inc. Combined drug delivery methods and apparatus
EP2600920A4 (en) 2010-08-05 2017-10-04 Forsight Vision4, Inc. Subconjunctival implant for posterior segment drug delivery
US9084976B2 (en) 2010-09-03 2015-07-21 Bend Research, Inc. Spray-drying apparatus and methods of using the same
US10307372B2 (en) 2010-09-10 2019-06-04 The Johns Hopkins University Rapid diffusion of large polymeric nanoparticles in the mammalian brain
CA2816977C (en) 2010-11-05 2019-10-29 The Johns Hopkins University Compositions and methods relating to reduced mucoadhesion
WO2012065006A2 (en) 2010-11-11 2012-05-18 Forsight Vision4, Inc. Methods and apparatus to determine porous structures for drug delivery
TW201304822A (en) 2010-11-15 2013-02-01 Vectura Ltd Compositions and uses
WO2012068549A2 (en) 2010-11-19 2012-05-24 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
WO2012093101A1 (en) 2011-01-04 2012-07-12 Novartis Ag Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (amd)
US9327037B2 (en) 2011-02-08 2016-05-03 The Johns Hopkins University Mucus penetrating gene carriers
WO2012145801A1 (en) 2011-04-29 2012-11-01 Jagat Rakesh Kanwar Nanoparticle
RU2639521C2 (en) 2011-05-05 2017-12-21 ВЕЛЛСТАТ ИММЬЮНОТЕРАПЬЮТИКС, ЭлЭлСи Analogues of complement factor b and their application
US9084727B2 (en) 2011-05-10 2015-07-21 Bend Research, Inc. Methods and compositions for maintaining active agents in intra-articular spaces
US8691750B2 (en) 2011-05-17 2014-04-08 Axolabs Gmbh Lipids and compositions for intracellular delivery of biologically active compounds
US8863971B2 (en) 2011-06-29 2014-10-21 Rehrig Pacific Company Crate with retractable wall
JP5721197B2 (en) 2011-06-29 2015-05-20 Ｎｅｃソリューションイノベータ株式会社 Three-dimensional feature data generation device, three-dimensional feature data generation method, and three-dimensional feature data generation program
EP2739252A4 (en) 2011-08-05 2015-08-12 Forsight Vision4 Inc Small molecule delivery with implantable therapeutic device
KR102071083B1 (en) 2011-09-14 2020-01-29 포사이트 비젼5, 인크. Ocular insert apparatus and methods
GB201115874D0 (en) 2011-09-14 2011-10-26 Astrazeneca Ab Inhaler
SI2755600T1 (en) 2011-09-16 2021-08-31 Forsight Vision4, Inc. Fluid exchange apparatus
EP2785326A2 (en) 2011-11-29 2014-10-08 The University of North Carolina at Chapel Hill Geometrically engineered particles and methods for modulating macrophage or immune responses
CN104105507B (en) 2011-12-14 2020-03-24 约翰霍普金斯大学 Nanoparticles for enhancing mucosal penetration or reducing inflammation
CN102516232A (en) 2011-12-14 2012-06-27 无锡美克赛医药科技有限公司 ErbB2 micro-molecular selective inhibitor and application thereof
ES2711330T3 (en) 2011-12-27 2019-05-03 Vectura Gmbh Inhalation device with feedback system
RU2598627C2 (en) 2012-01-19 2016-09-27 Дзе Джонс Хопкинс Юниверсити Composition based on nanoparticles with improved penetration through mucous membranes
WO2013116061A1 (en) 2012-02-03 2013-08-08 Forsight Vision4, Inc. Insertion and removal methods and apparatus for therapeutic devices
NZ628562A (en) 2012-03-09 2015-08-28 Vectura Gmbh Mixing channel for an inhalation device and inhalation device
EP2825206A1 (en) 2012-03-16 2015-01-21 The Johns Hopkins University Controlled release formulations for the delivery of hif-1 inhibitors
AU2013232300B2 (en) 2012-03-16 2015-12-17 The Johns Hopkins University Non-linear multiblock copolymer-drug conjugates for the delivery of active agents
US20140107025A1 (en) 2012-04-16 2014-04-17 Jade Therapeutics, Llc Ocular drug delivery system
JP6360040B2 (en) 2012-05-03 2018-07-18 カラ ファーマシューティカルズ インコーポレイテッド Mucus-permeable coated particles, compositions, pharmaceutical compositions, pharmaceutical formulations, and methods for forming them
EP4008355A1 (en) 2012-05-03 2022-06-08 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
PE20150623A1 (en) * 2012-05-04 2015-05-17 Novartis Ag MODULATORS OF THE COMPLEMENT ROUTE AND USES OF THEM
EP2849728A1 (en) 2012-05-04 2015-03-25 The Johns Hopkins University Lipid-based drug carriers for rapid penetration through mucus linings
AU2013277154A1 (en) * 2012-06-20 2014-12-18 Jonathan E. Grob Complement pathway modulators and uses thereof
US9487483B2 (en) 2012-06-28 2016-11-08 Novartis Ag Complement pathway modulators and uses thereof
EP2867226B1 (en) 2012-06-28 2018-11-14 Novartis AG Complement pathway modulators and uses thereof
WO2014002053A1 (en) 2012-06-28 2014-01-03 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
MX2014015738A (en) 2012-06-28 2015-08-06 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators.
CN104619698B (en) 2012-06-28 2016-08-31 诺华股份有限公司 Pyrrolidin derivatives and the purposes as complement pathway regulator thereof
JP6154897B2 (en) 2012-06-28 2017-06-28 ノバルティス アーゲー Pyrrolidine derivatives and their use as complement pathway regulators
WO2014002059A1 (en) 2012-06-29 2014-01-03 Novartis Ag CRYSTALLINE FORMS OF 1-(2-((1R,3S,5R)-3-(((R)-1-(3-chloro-2-fluorophenyl)ethyl)carbamoyl)-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-1Hpyrazolo[3,4-c]pyridine-3-carboxamide
WO2014005150A1 (en) 2012-06-29 2014-01-03 Novartis Ag Crystalline forms of l-(2-((lr,3s,5r)-3-( (2 -fluoro-3 - (trifluoromethoxy) phenyl) carbamoyl) - 2 -azabicycl o [3.1.0] hexan- 2 -yl) - 2 -oxoethyl) - 5 -methyl - 1h - pyrazolo [3, 4 -c] pyridine - 3 - carboxami de and salts thereof
CN104684910B (en) 2012-07-12 2016-10-12 诺华股份有限公司 Complement is by way of regulator and application thereof
ES1077714Y (en) 2012-07-31 2012-12-20 Gutierrez Jose Ramon Perez Wooden container
WO2014035876A1 (en) 2012-08-27 2014-03-06 William Marsh Rice University Heat-inactivated complement factor b compositions and methods
KR20150056619A (en) 2012-09-17 2015-05-26 바인드 쎄라퓨틱스, 인크. Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same
MX2015003665A (en) 2012-09-20 2016-03-08 Akina Inc Biodegradable microcapsules containing filling material.
PL2724741T3 (en) 2012-10-26 2017-11-30 Vectura Gmbh Inhalation device for use in aerosol therapy
DK2911623T3 (en) 2012-10-26 2019-10-28 Forsight Vision5 Inc Ophthalmic system for long-term release of drug into the eye
WO2014143638A1 (en) 2013-03-14 2014-09-18 Novartis Ag 2-(1h-indol-4-ylmethyl)-3h-imidazo[4,5-b]pyridine-6-carbonitrile derivatives as complement factor b inhibitors useful for the treatment of ophthalmic diseases
EP2968113B8 (en) 2013-03-14 2020-10-28 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
ES2972168T3 (en) 2013-03-28 2024-06-11 Forsight Vision4 Inc Ophthalmic implant for administration of therapeutic substances
JP6570513B2 (en) 2013-04-01 2019-09-04 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ Microsphere drug delivery system for sustained intraocular release
JO3425B1 (en) 2013-07-15 2019-10-20 Novartis Ag Piperidinyl indole derivatives and their use as complement factor b inhibitors
KR20160036568A (en) 2013-07-18 2016-04-04 노파르티스 아게 Aminomethyl-biaryl derivatives as complement factor d inhibitors and uses thereof
EP3043827B1 (en) 2013-09-13 2019-07-03 Ionis Pharmaceuticals, Inc. Modulators of complement factor b
AU2014334636A1 (en) 2013-10-15 2016-06-02 Forsight Vision5, Inc. Formulations and methods for increasing or reducing mucus
US9676728B2 (en) 2013-10-30 2017-06-13 Novartis Ag 2-benzyl-benzimidazole complement factor B inhibitors and uses thereof
WO2015085234A1 (en) 2013-12-06 2015-06-11 Forsight Vision4, Inc. Implantable therapeutic devices
AU2014360184B2 (en) 2013-12-06 2020-07-23 Allergan, Inc Intracameral implant for treatment of an ocular condition
SG11201811491YA (en) * 2016-06-27 2019-01-30 Achillion Pharmaceuticals Inc Quinazoline and indole compounds to treat medical disorders

Also Published As

Publication number Publication date
US10961252B2 (en) 2021-03-30
US20190135825A1 (en) 2019-05-09
CA3029262A1 (en) 2018-01-04
JP2019527203A (en) 2019-09-26
US11248000B2 (en) 2022-02-15
IL263783A (en) 2019-01-31
KR20190036520A (en) 2019-04-04
CN109414441A (en) 2019-03-01
EP3448389A1 (en) 2019-03-06
EP3448389B1 (en) 2021-09-29
JP2022091984A (en) 2022-06-21
WO2018005552A1 (en) 2018-01-04
EP3939591A1 (en) 2022-01-19
EP3448389A4 (en) 2019-10-30
US20200165262A1 (en) 2020-05-28
RU2018145364A (en) 2020-07-28
ES2902006T3 (en) 2022-03-24
MX2018016046A (en) 2019-05-02
AU2017290593A1 (en) 2019-01-03
JP7057290B2 (en) 2022-04-19
US20220119400A1 (en) 2022-04-21

Similar Documents

Publication Publication Date Title
SG11201811491YA (en) Quinazoline and indole compounds to treat medical disorders
SG11201909955XA (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11201900163PA (en) Macrocycle kinase inhibitors
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201900349VA (en) Somatostatin modulators and uses thereof
SG11201808990QA (en) Compositions for topical application of compounds
SG11201804814YA (en) Materials and methods for delivering nucleic acids to cochlear and vestibular cells
SG11201804373VA (en) Compositions and methods for immunooncology
SG11201811564QA (en) Methods of treating ovarian cancer
SG11201408318RA (en) Compositions and methods for transmucosal absorption
SG11201500005SA (en) Pyrimidine pyrazolyl derivatives
SG11201808566WA (en) Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide
SG11201807784SA (en) 3-desoxy derivative and pharmaceutical compositions thereof
SG11201808237UA (en) Substituted indole compound derivatives as dengue viral replication inhibitors
SG11201900238UA (en) Compounds and methods for modulation of smn2
SG11201808713YA (en) Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier
SG11201909807TA (en) Methods of manufacturing of niraparib
SG11201804704PA (en) Compositions and methods for decreasing tau expression
SG11201805001UA (en) Method of treating influenza a
SG11201903076QA (en) Carbamoyl phenylalaninol compounds and uses therof
SG11201902531QA (en) Liquid pharmaceutical composition
SG11201810143PA (en) Exon skipping oligomers for muscular dystrophy
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases
SG11201903230QA (en) TCRa HOMING ENDONUCLEASE VARIANTS
SG11201901925RA (en) Methods of treating acute kidney injury